학술논문
Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis
Document Type
Article
Author
Source
In: Inflammatory Bowel Diseases . (Inflammatory Bowel Diseases, 1 January 2024, 30(1):64-77)
Subject
Language
English
ISSN
15364844
10780998
10780998